Clinical Trial Update: JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of JS207 combined with chemotherapy for stage II-III non-small cell lung cancer is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JS207

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING